Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer

https://doi.org/10.1016/j.bmcl.2009.12.042Get rights and content

Abstract

Through conformational restriction of a benzamide by formation of a seven-membered hydrogen-bond with an oxindole carbonyl group, a series of PARP inhibitors was designed for appropriate orientation for binding to the PARP surface. This series of compounds with a 3-oxoisoindoline-4-carboxamide core structure, displayed modest to good activity against PARP-1 in both intrinsic and cellular assays. SAR studies at the lactam nitrogen of the pharmacophore have suggested that a secondary or tertiary amine is important for cellular potency. An X-ray structure of compound 1e bound to the protein confirmed the formation of a seven-membered intramolecular hydrogen bond. Though revealed previously in peptides, this type of seven-membered intramolecular hydrogen bond is rarely observed in small molecules. Largely due to the formation of the intramolecular hydrogen bond, the 3-oxoisoindoline-4-carboxamide core structure appears to be planar in the X-ray structure. An additional hydrogen bond interaction of the piperidine nitrogen to Gly-888 also contributes to the binding affinity of 1e to PARP-1.

Graphical abstract

We have discovered a series of compounds with a 3-oxoisoindoline-4-carboxamide core structure as potent PARP inhibitors. The highlight of the core is a conformational restriction of a benzamide by formation of a seven-membered hydrogen-bond with an oxindole carbonyl group, with compound 1e identified as the most potent in vitro PARP-1 inhibitor.

  1. Download : Download full-size image

Section snippets

Acknowledgment

The authors are grateful to the Abbott analytical department for acquisition of 1H NMR and MS.

References and notes (18)

  • D. Bellocchi et al.

    Bioorg. Med. Chem.

    (2005)
    P. Jagtap et al.

    Nat. Rev. Drug Disc.

    (2005)
  • V. Cepeda et al.

    Recent Patents on Anticancer Drug Discovery

    (2006)
  • T.D. Penning et al.

    Bioorg. Med. Chem.

    (2008)
    R.J. Griffin et al.

    Pharm. Sci.

    (1996)
    A.W. White et al.

    J. Med. Chem.

    (2000)
  • T.D. Penning et al.

    J. Med. Chem.

    (2009)
  • R.G. Lapidus et al.

    J. Clin. Oncol

    (2005)
  • L. Tentori et al.

    Clin. Cancer Res.

    (2003)
  • L. Virág et al.

    Pharmacol. Rev.

    (2002)
  • D. Dunn et al.

    Bioorg. Med. Chem. Lett.

    (2007)
    K.A. Menear et al.

    Bioorg. Med. Chem. Lett.

    (2008)
  • G.-D. Zhu et al.

    Bioorg. Med. Chem. Lett.

    (2008)
There are more references available in the full text version of this article.

Cited by (37)

  • Synthesis of heterocycles by utilizing phthalaldehydic acid: An overview

    2022, Tetrahedron
    Citation Excerpt :

    Along the same lines, compounds containing oxoisoindoline 1 core represent precious and interesting pharmacological and biological activities and these compounds are significantly paid immense attention by researchers. This scaffold is noticed due to its aggrecanase inhibition [15] (useful in osteoarthritis treatment), HIV-1 integrase inhibition [16], PARP inhibition [17] (useful in cancer treatment), Covalent Prolyl Oligopeptidase Inhibition [18], β1, β2-adrenergic antagonism [19] and Voltage-Gated Sodium Channel NaV1.7 blocking [20] effects. The intended scaffold is expected to exhibit novel activities (Fig. 2).

  • Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment

    2020, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Poly (ADP-ribose) polymerase (PARP) is a DNA repair enzyme essential for DNA replication, chromatin remodeling and apoptosis [103,104]. PARP is overexpressed in many blood and solid tumors [105]. Studies have shown that both PARP inhibitors and HDAC inhibitors can enhance the sensitivity of other antineoplastic drugs [106,107].

  • Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1

    2017, European Journal of Medicinal Chemistry
    Citation Excerpt :

    SAA, a derivative of the drug SAHA, has been reported to exert HDAC inhibitory activity [13] by carboxylic acid groups partially chelating with zinc ions and the aromatic groups occupying the tubular pocket. In addition, it is also found to possess PARP inhibitory activity with benzamide, a major pharmacophoric group in many PARP inhibitors [14], to form multiple hydrogen bonds with two critical amino acid residues in the PARP active site, Gly-863 and Ser-904 [15–17]. PARP-1 is regarded as a valuable target in the prospecting cancer treatment due to its key role in the repair of DNA strand breaks [18,19].

  • PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis

    2013, Current Opinion in Structural Biology
    Citation Excerpt :

    The helical subdomain (HD) of the CAT is composed of six α-helices with connecting linkers of variable sizes [12]. The majority of PARP-1 structural analysis has focused on the CAT domain, and there is a growing collection of structures of the CAT domain bound to PARP inhibitors [12,20,22–29], thus defining features of the catalytic active site and pointing to new avenues for drug design. There are also apo and inhibitor-bound structures determined for the catalytic domains of related PARP family members [30–38], which will help to understand the variation of catalytic activities [i.e. mono(ADP-ribose) versus poly(ADP-ribose) production], and will guide the design of more potent and specific inhibitors.

View all citing articles on Scopus
View full text